Immunic AG Logo

Immunic AG

Developing oral therapies for autoimmune diseases like multiple sclerosis and celiac disease.

IMUX | NDAQ

Overview

Corporate Details

ISIN(s):
US4525EP1011
LEI:
549300R5T12FW5MEQB20
Country:
United States of America
Address:
C/O The Corporation Trust Company, 19801 Wilmington
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Immunic, Inc. is a clinical-stage biotechnology company developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's development programs focus on creating convenient treatment options with high efficacy and favorable safety and tolerability profiles to address significant unmet patient needs. Its primary therapeutic areas of focus include multiple sclerosis and celiac disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 12:30
Regulatory News Service
Immunic to Participate in Scientific and Investor Conferences in October
English 14.9 KB
2025-09-25 12:30
Regulatory News Service
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS…
English 23.6 KB
2025-09-09 12:30
Regulatory News Service
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofl…
English 13.9 KB
2025-09-04 12:30
Regulatory News Service
Immunic to Participate in Investor and Scientific Conferences in September
English 15.6 KB
2025-08-07 12:30
Earnings Release
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corpor…
English 23.5 KB
2025-06-24 12:30
Regulatory News Service
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 …
English 15.2 KB
2025-06-05 12:30
Legal Proceedings Report
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Re…
English 18.3 KB
2025-06-02 12:30
Regulatory News Service
Immunic to Participate in Investor, Scientific and Industry Conferences in June
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all Immunic AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Immunic AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.